Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

633
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
633
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

578
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
578
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

491
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
491

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid growth of a long-standing dermal nodule in a young Black man: Clinical correlation in an ALK-rearranged epithelioid/spindle cell tumor.

JAAD case reports·2026
Same author

The Impact of Early Incomplete Sections on Mohs Micrographic Surgery Margin Assessment.

Clinical and experimental dermatology·2026
Same author

Beefing Up Awareness: Navigating Alpha-Gal Syndrome.

Clinical journal of oncology nursing·2026
Same author

Safety of dermatologic surgery during immune checkpoint inhibitor therapy.

Journal of the American Academy of Dermatology·2026
Same author

Hydrostatic Pressures in Lymphatic Networks of the Mouse.

Microcirculation (New York, N.Y. : 1994)·2025
Same author

Roles of G-protein coupled receptors and mechanosensitive ion channels in pressure-induced chronotropy of lymphatic vessels.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jul 26, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

882

Clinical Features Associated with Acute Elevated Intraocular Pressure After Intravitreal Anti-VEGF Injections.

Stephen A LoBue1,2, Sofya Gindina2, Nicholas J Saba2

  • 1Department of Ophthalmology, Acuity Eye Group, Pasadena, CA, USA.

Clinical Ophthalmology (Auckland, N.Z.)
|June 19, 2023
PubMed
Summary

Intravitreal injections of anti-VEGF agents can cause temporary intraocular pressure (IOP) spikes, especially in patients with glaucoma history. Careful needle selection is advised to manage these acute pressure changes after anti-VEGF therapy.

Keywords:
acute pressure spikesanterior chamber paracentesisanti-VEGFglaucomaintravitreal injection

More Related Videos

Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

237

Related Experiment Videos

Last Updated: Jul 26, 2025

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

882
Intravitreal Injections in the Ovine Eye
03:37

Intravitreal Injections in the Ovine Eye

Published on: July 5, 2022

3.3K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

237

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Vascular Biology

Background:

  • Intravitreal injections (IVI) of anti-VEGF agents are standard treatments for various retinal conditions.
  • Monitoring intraocular pressure (IOP) post-IVI is crucial for patient safety.
  • Acute IOP spikes can occur following IVI, necessitating further investigation.

Purpose of the Study:

  • To evaluate the impact of anti-VEGF IVI on intraocular pressure (IOP).
  • To identify factors associated with acute IOP spikes after IVI.
  • To assess the need for interventions like anterior chamber paracentesis (ACP).

Main Methods:

  • A prospective, three-month study involving 617 patients undergoing IVI for diabetic retinopathy, AMD, or RVO.
  • IOP was measured pre- and post-injection at 10-minute intervals up to 50 minutes.
  • Anterior chamber paracentesis (ACP) was performed if IOP exceeded 35 mmHg at 30 minutes.

Main Results:

  • 17 patients (2.8%) required ACP, with higher baseline IOP in this group (24 ± 7 mmHg vs. 16 ± 4 mmHg).
  • A history of glaucoma and higher pre-injection IOP (>25 mmHg) were associated with ACP.
  • Use of a 31-gauge needle correlated with a greater IOP increase compared to a 30-gauge needle.

Conclusions:

  • IOP spikes after IVI are common but usually transient, resolving within an hour.
  • Patients with glaucoma history and elevated pre-injection IOP may be at higher risk for prolonged IOP spikes with smaller gauge needles.
  • Consideration of needle gauge in high-risk patients is recommended to mitigate significant IOP elevations.